ESR1 and non-small cell lung carcinoma: Several in vitro and in vivo studies have shown enhanced effects when combining gefitinib and an ER inhibitor (e.g. tamoxifen or fulvestrant) in NSCLC, possibly providing a rationale for combining EGFR-TKIs with anti-estrogen therapy10, 11.